SANGAMO THERAPEUTICS, INC (SGMO)
SANGAMO THERAPEUTICS, INC (SGMO)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -30,995 | -37,419 | -34,930 | -50,583 |
| Impairment of long-lived assets | NaN | 13,235 | 0 | 0 |
| Depreciation and amortization | 719 | 959 | 989 | 2,013 |
| Amortization in operating lease right-of-use assets | 158 | 924 | 909 | 1,808 |
| Stock-based compensation | 992 | 2,130 | 2,127 | 4,822 |
| Accretion of discount on marketable securities | NaN | NaN | 0 | 0 |
| Gain on sale of assets classified as held for sale | NaN | 0 | NaN | NaN |
| Deferred income tax benefit | 0 | NaN | 0 | NaN |
| Other | 0 | 3 | 0 | -35 |
| Interest receivable | NaN | NaN | 0 | 0 |
| Accounts receivable | 502 | -152 | 151 | -154 |
| Prepaid expenses and other assets | -1,201 | -4,055 | 1,836 | 1,389 |
| Refundable research income tax credits | -4,525 | 0 | 0 | 0 |
| Accounts payable and other accrued liabilities | 4,936 | -1,506 | 3,999 | 301 |
| Other non-current liabilities | NaN | -397 | 15 | 30 |
| Accrued compensation and employee benefits | 630 | 572 | 1,717 | 764 |
| Lease liabilities | -449 | -448 | -1,337 | -2,262 |
| Deferred revenues | -497 | -6,657 | 0 | NaN |
| Net cash used in operating activities | -19,282 | -24,403 | -28,498 | -44,307 |
| Maturities of marketable securities | NaN | 0 | 0 | 0 |
| Proceeds from sale of marketable securities | NaN | 0 | 0 | 0 |
| Proceeds from sale of assets classified as held for sale | NaN | 0 | 0 | 0 |
| Purchases of property and equipment | 13 | 14 | 64 | 24 |
| Net cash used in investing activities | -13 | -14 | -64 | -24 |
| Proceeds from issuance of common stock under employee stock purchase plan | NaN | 164 | 1 | 179 |
| Proceeds from issuance of common stock, net of offering expenses | 23,346 | 0 | -106 | 21,589 |
| Proceeds from at-the-market offering, net of offering expenses | 3,732 | 14,982 | 19,576 | 17,627 |
| Taxes paid related to net share settlement of equity awards | 379 | 349 | 267 | 2,647 |
| Net cash provided by financing activities | 26,699 | 14,797 | 19,204 | 36,748 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | -766 | 40 | 42 | 4,009 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 6,638 | -9,580 | -9,316 | -3,574 |
| Cash, cash equivalents, and restricted cash, beginning of period | 20,948 | 30,528 | 43,418 | NaN |
| Cash, cash equivalents, and restricted cash, end of period | 27,586 | 20,948 | 30,528 | NaN |